Frustrated Boehringer breaks off German Trajenta price talks
This article was originally published in Scrip
Boehringer Ingelheim is breaking off price negotiations for its DPP-4 inhibitor Trajenta (linagliptin) with the GKV, the German association of sickness funds, the firm has told Scrip. The move comes as the company's frustration mounts with the new early benefit assessments that all new drugs must undergo in Germany.
You may also be interested in...
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.
The pharma and biotech industries have welcomed Australia’s coronavirus recovery budget, which also sets aside funding for research into COVID-19 vaccines and makes positive changes to R&D tax incentives.